Introduction
and Objective: Hepatoblastoma is the most frequent malignant
embryonal liver tumor, and its incidence is increasing. Children under 3 years
of age are particularly affected. The etiology is largely unknown, but a
genetic predisposition exists. This case highlights the clinical and imaging
characteristics and management strategies.Case Report: We report the case of an 18
months old male admitted for exploration of an abdominal mass and was diagnosed
with hepatoblastoma. Conclusion: Hepatoblastoma is an aggressive tumor that begins locally and eventually
metastasizes to the brain, lungs, lymph nodes, and other organs. Tumor
stage at presentation and resectability are the most significant prognostic
factors.
References
[1]
Herzog, C.E., Andrassy, R.J. and Eftekhari, F. (2000) Childhood Cancers: Hepatoblastoma. The Oncologist, 5, 445-453. https://doi.org/10.1634/theoncologist.5-6-445
[2]
Kahla, J.A., Siegel, D.A., Dai, S.F., Lupo, P.J., Foster, J.H., Scheurer, M.E. and Heczey, A.A. (2022) Incidence and 5-Year Survival of Children and Adolescents with Hepatoblastoma in the United States. Pediatric Blood Cancer, 69, e29763.
https://doi.org/10.1002/pbc.29763
[3]
Bharti, S., Bharti, J.N., Sinha, A. and Yadav, T. (2021) Common and Rare Histological Variants of Hepatoblastoma in Children: A Pathological Diagnosis and Review of the Literature. Gastrointest Tumors, 8, 41-46. https://doi.org/10.1159/000512236
[4]
Lucas, B., Ravishankar, S. and Pateva, I. (2021) Pediatric Primary Hepatic Tumors: Diagnostic Considerations. Diagnostics (Basel), 11, 333.
https://doi.org/10.3390/diagnostics11020333
[5]
Brugières, L., Branchereau, S. and Laithier, V. (2012) Paediatric Malignant Liver Tumours. Bulletin du Cancer, 99, 219-228. https://doi.org/10.1684/bdc.2011.1539
[6]
Heck, J.E., Meyers, T.J., Lombardi, C., Park, A.S., Cockburn, M., Reynolds, P. and Ritz, B. (2013) Case-Control Study of Birth Characteristics and the Risk of Hepatoblastoma. Cancer Epidemiology, 37, 390-395.
https://doi.org/10.1016/j.canep.2013.03.004
[7]
Purcell, R., Childs, M., Maibach, R., Miles, C., Turner, C., Zimmermann, A., Czauderna, P. and Sullivan, M. (2012) Potential Biomarkers for Hepatoblastoma: Results from the SIOPEL-3 Study. European Journal of Cancer, 48, 1853-1859.
https://doi.org/10.1016/j.ejca.2011.10.019
[8]
Taque, S., Buendia, M.A., Fabre, M., Branchereau, S., Pariente, D., Bruneau, B. and Brugières, L. (2013) What We Have to Know about Paediatrics Hepatoblastoma. Revue d’Oncologie Hématologie Pédiatrique, 1, 111-119.
https://doi.org/10.1016/j.oncohp.2013.10.003
[9]
Hiyama, E. (2014) Pediatric Hepatoblastoma: Diagnosis and Treatment. Translational Pediatrics, 3, 293-299.
[10]
Roebuck, D.J., Aronson, D., Clapuyt, P., Czauderna, P., de Ville de Goyet, J., Gauthier, F., MacKinlay, G., Maibach, R., McHugh, K., Olsen, Y.E., Otte, J.-B., Pariente, D., Plaschkes, J., Childs, M. and Perilongo, G. (2007) 2005 PRETEXT: A Revised Staging System for Primary Malignant Liver Tumours of Childhood Developed by the SIOPEL Group. Pediatric Radiology, 37, 123-132.
https://doi.org/10.1007/s00247-006-0361-5
[11]
Häberle, B., Bode, U. and von Schweinitz, D. (2003) Differentiated Treatment Protocols for High- and Standard-Risk Hepatoblastoma—An Interim Report of the German Liver Tumor Study HB99. Klinische Padiatrie, 215, 159-165.
[12]
Zsiros, J., Brugieres, L., Brock, P., Roebuck, D., Maibach, R., Zimmermann, A., et al. (2013) Dose-Dense Cisplatin-Based Chemotherapy and Surgery for Children with High-Risk Hepatoblastoma (SIOPEL-4): A Prospective, Single-Arm, Feasibility Study. The Lancet Oncology, 14, 834-842. https://doi.org/10.1016/S1470-2045(13)70272-9
[13]
Pihlajoki, M., Eloranta, K., Nousiainen, R., Väyryne, V., Soini, T., Kyrönlahti, A., Parkkila, S., Kanerva, J., Wilson, D.B., Pakarinen, M.P. and Heikinheimo, M. (2023) Biology of Childhcood Hepatoblastoma and the Search for Novel Treatments. Advances in Biological Regulation, 91, 100997.
https://doi.org/10.1016/j.jbior.2023.100997
